The Pharmaceutical Benefits Advisory Committee has recommended that mifepristone (RU486) and another drug taken in conjunction, misoprostol, be covered by the Pharmaceutical Benefits Scheme. In the coming weeks the Government will consider the recommendation and a decision is expected to be made prior to the election. More information is available here.